The stock of Outlook Therapeutics has staged a remarkable recovery, gaining nearly 30% in a single week to close at $1.58. That puts the biotech name comfortably above the Nasdaq’s $1.00 minimum bid threshold for now, but the real test lies in a pair of critical events crammed into the next few weeks.
On 16 July 2026, shareholders will gather in Chicago for an extraordinary general meeting. Among the three items on the agenda is a proposal to authorize a reverse stock split ranging from 1:10 to 1:50, with the board deciding the exact ratio. The stated purpose is to meet Nasdaq’s continued listing requirement. The stock must trade at $1.00 or more for at least ten consecutive trading sessions before the 17 August deadline. Nasdaq has not yet confirmed compliance, and the recent rally — fueled by regulatory news — has temporarily eased the pressure for a reverse split. But if the shares slip back, the authorization would serve as a safety net.
FDA Decision Looms on 29 July
The catalyst behind the week’s surge came from Washington. On 16 June 2026, the FDA confirmed receipt of the resubmitted Biologics License Application for ONS-5010/LYTENAVA, a treatment for wet age-related macular degeneration (neovascular AMD). The agency designated the filing as a Class 1 priority review, compressing the evaluation timeline. The PDUFA target date is 29 July — just 13 days after the shareholder vote.
This is the company’s fourth attempt at U.S. approval. Between 2023 and late 2025, Outlook Therapeutics received three rejection letters from the FDA. The latest submission follows a formal dispute resolution that was settled in May 2026, a step the company says confirmed the efficacy of its specially formulated bevacizumab version. If the FDA gives the green light, Lytenava would become the first ophthalmic bevacizumab specifically formulated for retinal diseases, potentially shaking up the market.
European Expansion Continues in the Background
While the U.S. decision hangs in the balance, the company is quietly building its European footprint. A new distribution agreement with Mediconsult AG secures market access in Switzerland, with a planned launch in 2027. Lytenava has already been approved in the European Union and the United Kingdom since 2024, and sales are underway in Germany, Austria, and the U.K.
Should investors sell immediately? Or is it worth buying Outlook Therapeutics?
The next few months also hold significance for competitors. Ocular Therapeutix and Ionis Pharmaceuticals are both expecting key FDA rulings, keeping the ophthalmology sector in focus.
Financial Pressures Remain Acute
For all the stock’s recent momentum, the balance sheet tells a different story. Outlook Therapeutics has stated that existing funds — including proceeds from an April 2026 offering — are insufficient to sustain operations for the next twelve months. The company has expressed “substantial doubt” about its ability to continue as a going concern.
To address that, the 16 July meeting also includes a proposal to increase authorized common shares from 260 million to 600 million. If certain warrant conditions are met, the company could raise up to $6.1 million in additional gross proceeds. Management has warned that if the vote fails, it may be forced to cut jobs, halt programs, or even file for bankruptcy.
The current share price, boosted by speculation, does not solve the underlying funding gap. With annualized 30-day volatility at 227%, the stock remains prone to sharp swings in either direction. The next few weeks will determine whether the rally holds long enough to see the FDA verdict through.
Ad
Outlook Therapeutics Stock: Buy or Sell?! New Outlook Therapeutics Analysis from June 20 delivers the answer:
The latest Outlook Therapeutics figures speak for themselves: Urgent action needed for Outlook Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 20.
Outlook Therapeutics: Buy or sell? Read more here...
